- GLUTAMATE DERIVATIVES OR SALTS THEREOF
-
Compounds having an excellent CaSR agonist activity are in demand. The invention provides glutamate derivatives or salts thereof, pharmaceutical compositions comprising the glutamate derivatives, preventive or therapeutic agents for diarrhea, hyperparathyroidism or peptic ulcer.
- -
-
Paragraph 0142
(2013/03/26)
-
- PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY
-
A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes or obesity is provided by a composition comprising the compound represented by general formula (I) as defined, or a salt thereof.
- -
-
Paragraph 0115
(2013/03/26)
-
- ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
-
This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
- -
-
Page/Page column 101; 102
(2013/12/03)
-
- SUBSTITUTED BENZENE COMPOUNDS
-
The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
- -
-
Page/Page column 280-281
(2012/11/06)
-
- CASR AGONIST
-
By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.
- -
-
Page/Page column 21
(2011/08/04)
-
- COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
-
The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.
- -
-
Page/Page column 75
(2010/11/24)
-
- ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD
-
Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C-R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.
- -
-
Page/Page column 42
(2010/02/10)
-
- Acyl guanidine sodium/proton exchange inhibitors and method
-
Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure STR1 wherein n is 1 to 5; X is N or C--R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.
- -
-
-